Prior progesterone treatments used included injection, oral/vaginal capsule, gel or another method. Of these women, 262 had used at least one progesterone treatment in a previous IVF cycle prior to entering the Phase III study. The survey assessed all 1,297 women in the trial, who used either Milprosa™ or progesterone gel. iĪdditionally, results from a patient satisfaction survey, which were part of the Phase III clinical trial, were also presented in a poster at ASRM.
"We look forward to having a new once-weekly option available for patients going through IVF. "We are encouraged by the data presented on Milprosa™ at ASRM this year, which demonstrated that the vaginal progesterone ring may provide an appropriate option for luteal phase support in IVF," said Mark Perloe, MD, medical director at Georgia Reproductive Specialists. Researchers concluded that Milprosa™ is effective in luteal supplementation in IVF and that clinical pregnancy rates were similar for the vaginal ring and 8 percent progesterone gel. Results showed clinical pregnancy rates for Milprosa™ were similar to progesterone gel, regardless of the day the embryos were returned to the uterus. These data were presented as an oral presentation at the 68 th Annual Meeting of the American Society for Reproductive Medicine (ASRM).ĭata from a randomized, single-blind trial assessing the pregnancy rate of Milprosa™ versus daily 8 percent progesterone gel for luteal supplementation in women undergoing embryo transfer during IVF at days three and five were presented. ( NYS: TEVA), today announced findings from a Phase III clinical trial of Milprosa TM (progesterone), an investigational weekly progesterone vaginal ring for luteal supplementation in women undergoing in vitro fertilization (IVF). Data Demonstrates Efficacy of the Vaginal Progesterone Ring, Milprosa™, is Similar to Progesterone Gel and May Offer a Convenient Administration Route for Women -įRAZER, Pa.-( BUSINESS WIRE)- Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. Announces New Data on Phase III Investigational Progesterone Vaginal Ring at the 68 th Annual Meeting of the American Society for Reproductive Medicine
0 kommentar(er)
